← Leaderboards
Keith Gottesdiener
Rhythm Pharmaceuticals, Inc.
$999,353
Attributed
$999,353
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $396.3K · FY2015–17$500K$375K$250K$125K$0
'15
'16
'17
Funding mix
By agency
FDA$999,353 · 1
By mechanism
R01$999,353 · 1
Top collaborators
No co-investigators on record.
Grant awards (3)
Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of Prader-Willi syndrome$210,406
R01 · FY2017 · FD · contact PI
Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of Prader-Willi syndrome$392,688
R01 · FY2016 · FD · contact PI
Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of Prader-Willi syndrome$396,259
R01 · FY2015 · FD · contact PI